Virtual Meetings 2023

Meet The Professor: Optimizing the Management of Gastroesophageal Cancers

For an up-to-date schedule of upcoming sessions in this series, please click here.


Peter C Enzinger, MD
Center for Esophageal and Gastric Cancer
Dana-Farber/Brigham and Women’s Cancer Center
Institute Physician, Dana-Farber Cancer Institute
Associate Professor, Harvard Medical School
Boston, Massachusetts

Samuel J Klempner, MD
Associate Professor
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospitals Leuven
Leuven, Belgium

Neil Love, MD
Research To Practice

These activities are supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, and Novartis.


Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for gastroesophageal cancers. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

Topics to Be Discussed

  • Current Role of Immune Checkpoint Inhibitors in the Management of HER2-Negative Gastroesophageal Cancers 
  • Emerging and Investigational Approaches to First-Line Therapy for Advanced Gastroesophageal Cancers
  • Optimal Management of HER2-Positive Gastroesophageal Cancers
  • Management of Relapsed/Refractory HER2-Negative Gastroesophageal Cancers

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastroesophageal cancers.

Learning Objectives

  • Use HER2 status, PD-L1 combined positive score, microsatellite instability status, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
  • Describe the published research data with anti-PD-1/PD-L1 antibodies administered alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
  • Optimally incorporate available therapeutic agents and regimens into the care of patients with HER2-negative metastatic gastric, GEJ and esophageal cancer who have experienced disease progression on front-line therapy.
  • Appraise clinical trial findings supporting the use of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal/GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease, and discern the clinical applicability of this treatment strategy.
  • Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric/GEJ cancer, and identify patients who may be appropriate for these approaches.
  • Evaluate the biological rationale for the investigation of CLDN18.2 as a therapeutic target in gastric/GEJ cancer, and assess available data with novel strategies directed at this potential biomarker.
  • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
  • Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr EnzingerConsulting Agreements: ALX Oncology, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Chimeric Therapeutics, Celgene Corporation, Coherus BioSciences, Daiichi Sankyo Inc, IDEAYA Biosciences, Istari Oncology, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck Sharp & Dohme LLC, Novartis, Ono Pharmaceutical Co Ltd, Servier Pharmaceuticals LLC, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc, Xencor, Zymeworks Inc. Dr Klempner Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Coherus BioSciences, Daiichi Sankyo Inc, Merck, Mersana Therapeutics Inc, Natera Inc, Pfizer Inc, Sanofi, Servier Pharmaceuticals LLC; Consulting Agreements: Astellas, Novartis; Medical Advisory Board (No Compensation): Debbie’s Dream Foundation, Hope for Stomach Cancer; Stock Options — Public Company: Nuvalent (ended 11/2022), Turning Point Therapeutics Inc (ended 6/2022); Nonrelevant Financial Relationship: American Gastroenterological Association, Degregorio Family Foundation, National Cancer Institute/National Institutes of Health, Stand Up 2 Cancer/AACR. Dr Van CutsemAdvisory Committee: AbbVie Inc, ALX Oncology, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, GSK, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Nordic Pharma, Novartis, Pfizer Inc, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Taiho Oncology Inc, Takeda Pharmaceutical Company Limited, Terumo Medical Corporation, Zymeworks Inc; Research Grants to Institution: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme LLC, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, and Novartis.